New Gamma-Secretase Inhibitors for Alzheimer's Disease Treatment
Elan Pharmaceuticals, Inc.
2010
n=5
publication
10 minutes
Evidence: moderate
Basi Guriqbal S, Hemphill Susanna, Brigham Elizabeth F, Liao Anna, Aubele Danielle L, Baker Jeanne, Barbour Robin, Bova Michael, Chen Xiao-Hua, Dappen Michael S, Eichenbaum Tovah, Goldbach Erich, Hawkinson Jon, Lawler-Herbold Rose, Hu Kang, Hui Terence, Jagodzinski Jacek J, Keim Pamela S, Kholodenko Dora, Latimer Lee H, Lee Mike, Marugg Jennifer, Mattson Matthew N, McCauley Scott, Miller James L, Motter Ruth, Mutter Linda, Neitzel Martin L, Ni Huifang, Nguyen Lan, Quinn Kevin, Ruslim Lany, Semko Christopher M, Shapiro Paul, Smith Jenifer, Soriano Ferdie, Szoke Balazs, Tanaka Kevin, Tang Pearl, Tucker John A, Ye Xiacong Michael, Yu Mei, Wu Jing, Xu Ying-zi, Garofalo Albert W, Sauer John Michael, Konradi Andrei W, Ness Daniel, Shopp George, Pleiss Michael A, Freedman Stephen B, Schenk Dale
Title
New Gamma-Secretase Inhibitors for Alzheimer's Disease Treatment
Hypothesis
APP substrate selective inhibitors of gamma-secretase would be preferable to non-selective inhibitors from a safety perspective for Alzheimer's disease therapy.
Conclusion
The discovery of ELN475516 demonstrates that it is possible to develop APP selective gamma-secretase inhibitors with potential for treatment for Alzheimer's disease.